Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Lamers

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Immunotherapy|July 9, 2013
Genetically modified T lymphocytes: more than just direct effectorsCor H J Lamers, Reno Debets
Nederlands Tijdschrift Voor Geneeskunde|October 26, 1974
[Tropical pyomyositis]J H Hewitten, H J Lamers
Stem Cell Investigation|June 14, 2017
Graft predominance after double umbilical cord blood transplantation: a reviewJan J Cornelissen, Burak Kalin, Cor H J Lamers
Immunotherapy|June 13, 2015
Adoptive T-cell therapy: a need for standard immune monitoringYarne Klaver, Andre Kunert, Stefan Sleijfer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
T-cell Receptors for Clinical Therapy: <i>In Vitro</i> Assessment of Toxicity RiskAndre Kunert, Matthias Obenaus, Cor H J Lamers, et al.
Biochemical Society Transactions|June 11, 2016
Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overviewCor H J Lamers, Yarne Klaver, Jan W Gratama, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 13, 1999
Dietary advice for acute diarrhoea in general practice: a pilot studyH J Lamers, R H Jamin, J O Zaat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2009
Quantification of circulating endothelial cells by flow cytometryMichiel H Strijbos, Jaco Kraan, Cor H J Lamers, et al.
Clinical Immunology (Orlando, Fla.)|July 6, 2016
Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cellsYarne Klaver, Sabine C L van Steenbergen, Stefan Sleijfer, et al.
Cancer Research|May 1, 1991
Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytesH J Lamers, J W Gratama, W L van Putten, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Immunotherapy|July 9, 2013
Genetically modified T lymphocytes: more than just direct effectorsCor H J Lamers, Reno Debets
Nederlands Tijdschrift Voor Geneeskunde|October 26, 1974
[Tropical pyomyositis]J H Hewitten, H J Lamers
Stem Cell Investigation|June 14, 2017
Graft predominance after double umbilical cord blood transplantation: a reviewJan J Cornelissen, Burak Kalin, Cor H J Lamers
Immunotherapy|June 13, 2015
Adoptive T-cell therapy: a need for standard immune monitoringYarne Klaver, Andre Kunert, Stefan Sleijfer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
T-cell Receptors for Clinical Therapy: <i>In Vitro</i> Assessment of Toxicity RiskAndre Kunert, Matthias Obenaus, Cor H J Lamers, et al.
Biochemical Society Transactions|June 11, 2016
Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overviewCor H J Lamers, Yarne Klaver, Jan W Gratama, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 13, 1999
Dietary advice for acute diarrhoea in general practice: a pilot studyH J Lamers, R H Jamin, J O Zaat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2009
Quantification of circulating endothelial cells by flow cytometryMichiel H Strijbos, Jaco Kraan, Cor H J Lamers, et al.
Clinical Immunology (Orlando, Fla.)|July 6, 2016
Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cellsYarne Klaver, Sabine C L van Steenbergen, Stefan Sleijfer, et al.
Cancer Research|May 1, 1991
Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytesH J Lamers, J W Gratama, W L van Putten, et al.
Pageof 5